⌕
Editas Medicine · EDIT · Nasdaq
Tenet 27 · Weak
Compare
$1.87−13.82%At closeTenet 27 · Weak
$1.87−0.30 (−13.82%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Editas Medicine (EDIT) Stock

Editas Medicine (EDIT) closed at $1.87 on Nov 16, 2026; its Tenet Score is 27 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$1.87
Nov 16, 2026
Market cap
$288.6M
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
1.66 – 3.94
low → high
Tenet Score
27/100
Weak · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Editas Medicine, Inc. scores 27/100. Weak. Quality is the soft spot versus 409 Healthcare peers.

Tenet Score · vs sector

n=409
27/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
52
Quality
7
Health
41
Growth
9

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueCQualityFHealthDGrowthFMomentumD
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
4.0×
cap ÷ Sep 30, 2026 book value, Nov 13, 2026 close
P/S
8.3×
price to fiscal 2025 sales
ROE
−147%
TTM through Sep 30, 2026
Operating margin
−394.9%
fiscal 2025, before interest and tax
Net margin
−139.8%
TTM through Sep 30, 2026
Current ratio
2.82
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDI…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 43 US ETFs · top wrappers by weightSee all ETFs holding EDIT →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Editas Medicine in?

Editas Medicine is in the Healthcare sector and the Drugs industry.

What is Editas Medicine's Tenet Score?

Editas Medicine's Tenet Score is 27 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.